Verve Therapeutics Stock Price, News & Analysis

Verve Therapeutics, Inc. (former Nasdaq: VERV) is a clinical-stage biotechnology company that has focused on developing a new class of genetic medicines for cardiovascular disease. According to company disclosures and recent news, Verve’s approach centers on single-course in vivo gene editing medicines designed to transform treatment from chronic, ongoing therapies to one-time interventions. The company has described its medicines as aiming to permanently turn off specific genes in the liver that drive atherosclerotic cardiovascular disease (ASCVD) and related lipid disorders.

Verve has been identified in public filings and press releases as a clinical-stage company with multiple programs in development. Its lead programs – VERVE-102, VERVE-201, and VERVE-301 – target what Verve describes as the three key lipoprotein or cholesterol drivers of atherosclerosis: low-density lipoprotein cholesterol (LDL-C), triglyceride-rich lipoproteins or triglycerides, and lipoprotein(a) [Lp(a)]. These programs are designed as single-course treatments that permanently turn off target genes in the liver to reduce disease-driving lipid levels.

Core programs and scientific focus

VERVE-102 is described in Verve’s news releases as an in vivo base editing medicine targeting the PCSK9 gene in the liver. It is designed as a single-course intravenous infusion that permanently turns off PCSK9 to durably lower LDL-C. Verve reports that VERVE-102 uses its proprietary GalNAc-LNP (galactosamine-conjugated lipid nanoparticle) delivery technology, intended to allow access to liver cells via the low-density lipoprotein receptor (LDLR) or the asialoglycoprotein receptor (ASGPR). VERVE-102 has been evaluated in the Heart-2 Phase 1b clinical trial in adults with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD) who require additional LDL-C lowering.

In public data from the Heart-2 trial, Verve has reported that a single infusion of VERVE-102 led to dose-dependent reductions in blood LDL-C and PCSK9 protein levels, with mean LDL-C reductions and a maximum reduction figure described across dose cohorts. The company has also stated that, among the participants reported, VERVE-102 was well-tolerated, with no treatment-related serious adverse events and no clinically significant laboratory abnormalities in the measures described.

VERVE-201 is described as an in vivo base editing medicine designed to permanently turn off the ANGPTL3 gene in the liver. According to Verve’s releases, this program is intended to reduce LDL-C as well as triglycerides and is being developed for patients with refractory hypercholesterolemia who remain with high LDL-C despite maximally tolerated standard of care therapies, and for individuals with homozygous familial hypercholesterolemia (HoFH). VERVE-201 is being evaluated in the Pulse-1 Phase 1b clinical trial, which Verve describes as an open-label study focusing on safety, tolerability, pharmacokinetics, and changes in blood ANGPTL3 protein and LDL-C levels.

VERVE-301 is described as an in vivo gene editing medicine designed to permanently turn off the LPA gene in the liver to reduce lipoprotein(a) [Lp(a)] levels. Verve characterizes Lp(a) as a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. The company has stated that VERVE-301 uses its GalNAc-LNP delivery technology and a novel gene editor, and that it has an exclusive research collaboration with Eli Lilly and Company to advance this program for lowering Lp(a) in ASCVD.

Therapeutic concept and disease focus

Across its programs, Verve describes a consistent therapeutic concept: single-course gene editing in adults to achieve durable reductions in disease-driving lipid parameters. The company’s public materials emphasize LDL-C, triglycerides, and Lp(a) as central drivers of atherosclerosis and cardiovascular risk. Verve has repeatedly stated that existing LDL-C-lowering options can be associated with transient reductions and frequent discontinuation, and that its goal is a “one-dose future” that could provide sustained lipid lowering for patients with high lifetime cardiovascular risk.

Verve’s work is positioned around patients with high cardiovascular risk, including those with heterozygous familial hypercholesterolemia, refractory hypercholesterolemia, homozygous familial hypercholesterolemia, and premature coronary artery disease, as described in its trial designs and program summaries. The company also highlights ASCVD more broadly, and the role of LDL-C and Lp(a) as validated risk factors.

Regulatory designations and clinical development

Verve has announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for VERVE-102 for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce LDL-C. Fast Track designation is described in Verve’s communications as a regulatory mechanism intended to facilitate development and expedite review of drugs that treat serious or life-threatening conditions and have the potential to address unmet medical needs.

The company has also disclosed that the FDA cleared an investigational new drug (IND) application for VERVE-102, enabling U.S. clinical trial sites to participate in studies such as the Heart-2 trial. Verve’s public updates describe ongoing dose-escalation, pharmacodynamic analyses by total RNA dose, and plans for further clinical development, including a Phase 2 trial for VERVE-102, subject to regulatory processes.

Acquisition by Eli Lilly and Company and trading status

According to a Form 8-K filed with the U.S. Securities and Exchange Commission (SEC) and related press releases, Verve Therapeutics entered into an Agreement and Plan of Merger with Eli Lilly and Company and Ridgeway Acquisition Corporation. A tender offer for all issued and outstanding shares of Verve’s common stock was commenced, and following satisfaction of the minimum tender condition and other conditions, the acquisition was completed. The SEC filing states that, on July 25, 2025, the purchaser was merged with and into Verve, with Verve continuing as the surviving corporation and becoming an indirect wholly-owned subsidiary of Eli Lilly and Company.

In connection with this transaction, Verve requested that the Nasdaq Stock Market LLC suspend trading of its common stock and file a Form 25 to remove the common stock from listing and registration on Nasdaq. A Form 25 (25-NSE) filed for Verve Therapeutics, Inc. confirms the notification of removal from listing and/or registration of its common stock on Nasdaq. Subsequently, Verve filed a Form 15 to terminate registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934 and to suspend its duty to file reports under Sections 13 and 15(d). The Form 15 notes that the approximate number of holders of record at the certification date was one holder.

As a result of these steps, Verve’s common stock is no longer listed on Nasdaq, and the company has suspended its periodic reporting obligations under the Exchange Act. The historical ticker symbol VERV therefore represents a former exchange-listed security that has been acquired and is now associated with a subsidiary of Eli Lilly and Company rather than an independent public company.

Historical background and mission

Earlier descriptions of Verve Therapeutics characterize it as a biotechnology company created with a focus on protecting people from heart disease by combining human genetics analysis and gene editing. The company has described its medicines as being administered once in life to edit the genome of adults, with the goal of permanently lowering LDL cholesterol and triglyceride levels to treat coronary heart disease and ASCVD. Verve has also been described as founded by experts in cardiovascular medicine, human genetics, and gene editing, and headquartered in the Boston/Cambridge, Massachusetts area.

Over time, Verve’s public communications have consistently emphasized its mission to move cardiovascular care from chronic, repeated treatment to single-course gene editing approaches. Its collaborations, including the exclusive research collaboration with Eli Lilly on the Lp(a) program, and its eventual acquisition by Eli Lilly, are part of this historical trajectory.

Position within the pharmaceutical and biotechnology landscape

Within the broader pharmaceutical preparation manufacturing and biotechnology sector, Verve is described in its own materials as a clinical-stage company developing genetic medicines for cardiovascular disease. Rather than focusing on small molecules or traditional biologics, Verve’s programs are centered on in vivo base editing and gene editing technologies delivered to the liver via lipid nanoparticles. Its work is concentrated on lipid disorders that are strongly linked to cardiovascular risk, including elevated LDL-C, triglycerides, and Lp(a).

For investors and researchers reviewing the historical VERV listing, it is important to recognize that Verve’s public equity has been acquired and delisted, and that the company’s ongoing activities, as described in SEC filings and news releases, are now conducted as part of Eli Lilly and Company. Historical information about Verve’s programs, regulatory designations, and clinical trial designs remains relevant for understanding the evolution of genetic medicines for cardiovascular disease and the development of single-course gene editing approaches in this therapeutic area.